This article is reserved for members

Already a member?

Log In

Not a member ?

Free registration
Azenta Swings to Fiscal Q2 Adjusted Profit, Revenue Increases; 2024 Guidance Updated; Chief Executive Schwartz to Retire MT
Earnings Flash (AZTA) AZENTA Reports Q2 Revenue $159.1M, vs. Street Est of $159.9M MT
Earnings Flash (AZTA) AZENTA Posts Q2 EPS $0.05, vs. Street Est of $0.02 MT
Transcript : Azenta, Inc., Q2 2024 Earnings Call, May 08, 2024
Azenta, Inc. Provides Earnings Guidance for the Full Fiscal Year 2024 CI
Stephen Schwartz to Retire as CEO of Azenta, Inc CI
Stephen Schwartz to Retire as Board Director of Azenta, Inc CI
Azenta, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended March 31, 2024 CI
Transcript : Azenta, Inc. Presents at 23rd Annual Needham Virtual Healthcare Conference, Apr-08-2024 12:45 PM
Evercore ISI Raises Azenta's Price Target to $60 From $64, Maintains In Line Rating MT
Jefferies Initiates Coverage on Azenta With Hold Rating, $64 Price Target MT
Azenta Seeks Tuck-In M&A CI
Transcript : Azenta, Inc. Presents at KeyBanc Capital Markets Virtual Life Sciences & MedTech Investor Forum, Mar-19-2024 12:45 PM
Nvidia's dizzying rally spurs rush into AI-themed ETFs RE
Transcript : Azenta, Inc. - Analyst/Investor Day
Needham Trims Price Target on Azenta to $75 From $76, Maintains Buy Rating MT
Azenta's Fiscal Q1 Non-GAAP Earnings, Revenue Decline MT
Transcript : Azenta, Inc., Q1 2024 Earnings Call, Feb 07, 2024
Azenta, Inc. Reports Earnings Results for the First Quarter Ended December 31, 2023 CI
Earnings Flash (AZTA) AZENTA Posts Q1 EPS $0.02, vs. Street Est of $-0.03 MT
Earnings Flash (AZTA) AZENTA Reports Q1 Revenue $154.3M, vs. Street Est of $151.2M MT
Azenta, Inc. Announces the Launch of the BioArc Ultra CI
Azenta, Inc. Announces Election of Directors CI
B. Riley Adjusts Azenta's Price Target to $79 From $61 Ahead of Fiscal Q1 Results Announcement, Keeps Buy Rating MT
Needham Adjusts Azenta's Price Target to $76 From $68, Keeps Buy Rating MT
Chart Azenta, Inc.
More charts
Azenta, Inc. is a provider of biological and chemical compound sample exploration and management solutions for the life sciences industry. The Company’s segments include Sample Management Solutions, Multiomics and B Medical Systems. The Sample Management Solutions segment offers end-to-end sample management products and services, including sample and repository services and core products (automated stores, cryogenic systems, automated sample tube, and consumables and instruments). The Multiomics segment provides genomic and other sample analysis services, including gene sequencing and gene synthesis. B Medical Systems segment is focused on the manufacturing and distribution of temperature-controlled storage and transportation solutions in international markets to governments, health institutions, and non-government organizations. It provides products and services through its brands, including GENEWIZ, FluidX, Ziath, 4titude, Limfinity, Freezer Pro, Barkey, and B Medical Systems.
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
B+
More Ratings
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
7
Last Close Price
54.07 USD
Average target price
66.8 USD
Spread / Average Target
+23.54%
Consensus
  1. Stock Market
  2. Equities
  3. AZTA Stock
  4. News Azenta, Inc.
  5. Earnings Flash (AZTA) AZENTA Posts Q1 EPS $0.02, vs. Street Est of $-0.03